A New Hope in Lupus Treatment: Gazvya (Obinutuzumab)

For decades, scientists, and clinicians have known that systemic lupus erythematosus (SLE), has a complex origin involving genetics, hormones, and environmental influences. Lupus posed major challenges for patients and physicians because treatment options are often only partially effective and can carry major side effects.

Recently, Gazvya (with the generic name Obinutuzumab), a monoclonal antibody originally developed to treat certain cancers, has emerged as one of the most promising new therapies for lupus.

*Disclaimer:

The information provided in this article is for general informational purposes only and is not intended as medical advice. It should not be used as a substitute for professional diagnosis, treatment, or advice from a qualified healthcare provider. Reliance on any information provided in this article is solely at your own risk.

See a word you don't understand? Find it in our glossary.

Gazyva is a Type II humanized anti-CD20 monoclonal antibody. This means that it is a lab-made protein designed to bind to a specific molecule called CD20 that exists on the surface of certain B-cells. By binding to CD20, Gazvya helps remove these B-cells from the body.

Gazvya was originally developed for the treatment of blood cancer, where it helps destroy malignant B-cells. Over time, researchers began studying whether its ability to deplete B-cells might be helpful in autoimmune diseases like lupus. In lupus, B-cells can contribute to inflammation and organ damage by producing harmful antibodies and activating other parts of the immune system.

One of the most exciting pieces of recent research comes from a Phase III clinical study called the ALLEGORY trial, which looked at the effectiveness of Gazyva in adults with SLE.

The ALLEGORY study enrolled adults with active SLE who continued their usual medications (standard of care) but were randomly assigned to receive either Gazyva or a placebo in addition to their regular treatment. The results showed that the group receiving Gazyva experienced significant reductions in lupus disease activity.

These results are important because efforts to make effective treatments for lupus have been difficult, with many candidates failing to show clear benefits in large-scale trials. The CD20-targeted approach showing promise in SLE suggests that deeper and more effective B-cell depletion B-cell depletion could help control the immune system’s attack on healthy tissue.

The most evidence for Gazvya in lupus comes from the REGENCY trial, a Phase III study focused specifically on kidney manifestations of lupus that can lead to kidney failure if not controlled. Important results from the REGENCY trial are summarized below.

• Nearly 46.4% of people treated with Gazyva plus standard therapy achieved a complete renal response at about 76 weeks, compared with around 33.1% of those receiving standard therapy alone.

• A complete renal response means that kidney function returned close to normal and protein levels in the urine (a sign of kidney damage) were reduced significantly.

The benefits of Gazvya were seen across diverse subgroups of patients, meaning the therapy could have broad applicability.

These results build on earlier Phase II data, which showed that Gazvya could preserve kidney function and lower the risk of lupus flares when added to standard immunosuppressive therapy. The results represent meaningful improvement in long-term kidney function and reduced progression to kidney failure. This is especially important because lupus affects many young people and can lead to lifelong health consequences.

Based on these strong results, the FDA approved Gazyva for the treatment of adults with lupus in October 2025. Additionally, the European Commission also approved Gazyva for lupus, treatment options for patients across the European Union based on similar Phase II and Phase III trial evidence.

However, like all therapies targeting the immune system, Gazyva can have side effects. The most common issues seen in clinical trials include infusion- related reactions and increased vulnerability to infection due to immune suppression. While clinicians always closely monitor patients, individual decisions about treatment should always be made in consultation with a doctor familiar with a person's medical history and current health status.​

As research continues to move, targeted therapies like Gazyva will not only improve outcomes for people with lupus but also reduce the long-term burden of this chronic disease and open doors to even more effective treatments.

In REGENCY, nearly half of patients treated with GAZYVA + ST achieved CRR1* | Gazvya

Important Safety Information and Indication | Gazvya

Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis | NIH

FDA Approves Gazyva® (obinutuzumab) for the Treatment of Adults with Lupus Nephritis | Lupus Foundation of America

Phase III Study Shows Positive Results for Gazyva® in Systemic Lupus Erythematosus | Lupus Foundation of America